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ABSTRACT 
 
 
 
 
EFFECTS OF HORMONE REPLACEMENT THERAPY ON SYSTEMIC ARTERIAL 
PROPERTIES IN POST-MENOPAUSAL WOMEN 
 
 
Eric Alps Chen, B.S. 
 
 
University of Pittsburgh, 2002 
 
 
 
Vascular stiffness properties contribute significantly to the arterial system 
hydraulic load.  There is evidence that vascular stiffness plays a role in cardiovascular 
remodeling and may be an independent cardiovascular risk factor.  Menopause 
accelerates age-associated increase in arterial stiffness and estrogen administration, which 
has vasodilating properties, can potentially mitigate this post-menopausal increase in 
stiffness.  
The present study examined the effects of chronic hormone replacement therapy 
(HRT) on systemic arterial mechanical properties in 35 post-menopausal women, divided 
into two groups: those receiving no HRT (Control, n = 25) and those receiving HRT 
(HRT-all, n = 10).  The HRT-all group consisted of two subgroups: estrogen alone (HRT-
E, n = 5) and a combination of estrogen and progesterone (HRT-EP, n = 5).  Noninvasive 
data were collected serially at five times: once at the baseline during the first visit and 
during four subsequent visits after the initiation of the study at 19±1, 108±5, 193±4, and 
 iv 
 388±8 days, respectively.  Heart rate (HR), stroke volume (SV), and cardiac output (CO) 
did not change significantly in the control group throughout the study.  This was also true 
for both HRT groups, except for a small decrease in HR at Visits 3 and 4 for the HRT-E 
group and an increase in CO at Visit 3 in the HRT-EP group.  Mean arterial pressure 
decreased over time in control and both HRT groups, reaching statistical significance at 
later times (fifth visit).  Systemic vascular resistance (SVR) did not change significantly 
in control and both HRT groups.  Global arterial compliance (AC) was unchanged for the 
control group but tended to increase in the HRT-all group, although no statistical 
significance was reached.  In contrast, the subgroup analysis revealed that AC increased 
for the HRT-E subgroup, reaching statistical significance at the fifth visit.  Similarly, 
significant decrements in pulse wave velocity (PWV), an index of regional vascular 
stiffness, were observed only for the HRT-E group.  
In conclusion, AC increased (vascular stiffness decreased) in subjects receiving 
chronic estrogen therapy only.  The inclusion of progesterone seems to counteract the 
estrogen-mediated decrease in vascular stiffness, indicating that the vascular stiffness-
associated cardio-protective effects of HRT, if any, may be limited to estrogen 
administration alone. 
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NOMENCLATURE 
 
 
Acronyms & Symbols 
 
 
 
AC  global arterial compliance  
Ad area underneath the diastolic portion of the carotid (aortic) pressure 
waveform 
CO  cardiac output  
DLVOT  left ventricular outflow tract diameter 
HR  heart rate 
HRT  hormone replacement therapy 
HRT-all group consisting of all subjects receiving hormone replacement therapy 
HRT-E group consisting of subjects receiving estrogen alone (a subset of HRT-all) 
HRT-EP group consisting of subjects receiving estrogen and progesterone (a subset 
of HRT-all) 
MAP  mean arterial pressure 
Pd  arterial minimum diastolic pressure 
Ps-carotid carotid peak systolic pressure 
Ps-brachial brachial peak systolic pressure 
PWVC-F carotid-to-femoral pulse wave velocity 
PWVB-R brachial-to-radial pulse wave velocity 
 xiv 
 P1  carotid peak pressure point following the dicrotic notch 
P2  carotid minimum diastolic pressure point (same as Pd) 
RI  global reflection index 
SV  stroke volume 
SVR  systemic vascular resistance 
td  duration of diastole 
Wtot  total power 
Wstd  steady power 
Wosc  oscillatory power 
%Wosc  percent oscillatory power 
Zc  carotid (aortic) characteristic impedance 
Zin  carotid (aortic) input impedance spectrum 
Z1  modulus of first (fundamental) harmonic of the input impedance spectrum 
|Γ1|  magnitude of the first harmonic of global reflection coefficient spectrum 
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1.0 INTRODUCTION 
 
Hardening of the pulse, first described thousands of years ago by Chinese healers, 
was known even then to be an adverse prognostic sign1.  In Western civilization, the 
changes in arterial stiffness with normal aging and certain pathological conditions (e.g., 
hypertension, arteriosclerosis) have been documented for some time now2.  Arterial 
stiffness is being recognized as a risk marker for coronary heart disease and is potentially 
modifiable2.  Epidemiological studies have shown that the incidence of cardiovascular 
disease and risks are lower in pre-menopausal women compared to similar-aged men, and 
these gender differences seem to disappear in the post-menopausal state3.  In some of the 
previous studies, there is evidence indicating that hormone replacement therapy (HRT) 
for post-menopausal women, which includes estrogen, significantly decreases 
cardiovascular disease and risks4,5.  The goal of the present study was to examine the 
long-term effects of HRT on systemic arterial mechanical properties in post-menopausal 
women. 
 
 
 
 
 
 
 
 
 
 
________________________________________________________________________ 
Note: All numerical references can be found in the bibliography. 
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 2.0 BACKGROUND 
 
2.1 Basic Principles of Systemic Arterial Function 
 
As discovered by the British physiologist William Harvey in 1628, the 
cardiovascular system contains two circuits: systemic and pulmonary circulations.  
Deoxygenated blood from the right ventricle is pumped through the pulmonary arterial 
circulation, oxygenated in the lungs, and returned to the left atrium.  Oxygenated blood is 
then pumped from the left ventricle into all organs and tissues (systemic arterial 
circulation) and then returns via the systemic venous circulation to the right atrium.  The 
present work focuses on the systemic arterial circulation, which begins with a single 
vessel originating from the left ventricle (ascending aorta) and subsequently divides into 
gradually smaller arteries.  These arteries ultimately branch into arterioles and then 
further into smaller vessels, capillaries. 
The basic functional and structural characteristics of systemic arteries change as 
they go from the aorta down to the capillaries.  All systemic arterial vessels are 
comprised of endothelial cells, smooth muscle, and connective tissue (e.g., elastin and 
collagenous fibers), except for capillaries that are primarily made up of endothelial cells.  
Endothelial cells form the inner lining of the vessels and possess a number of functions 
that play an important role in modulating arterial mechanical properties.  The level of 
smooth muscle activation and arterial vessel remodeling (i.e., vascular geometry, vessel 
wall mass, and relative amounts of elastin, collagen, and smooth muscle) also affect 
arterial mechanical properties. 
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 From the functional viewpoint, most of the hydraulic resistance to blood flow is 
provided by arterioles, which contain smooth muscle and have the ability to vasodilate 
(an increase in radius) or vasoconstrict (a decrease in radius).  It is clear that a number of 
substances can cause contraction or relaxation of vascular smooth muscle6.  Many of 
these substances act directly on the smooth muscle, but some of them act on the 
endothelial cells nearby the smooth muscle.  These endothelial cells respond to these 
substances by releasing paracrine agents that diffuse to the neighboring smooth muscle 
and cause vasodilation or vasoconstriction. 
In order to meet the continuous needs of peripheral tissues for oxygen and 
substrate delivery, the arterial tree must convert cardiac pulsations into a more constant 
flow pattern in the distal circulation1.  This conversion of pulsations occurs in the 
proximal vessels (aorta and large arteries) during systole.  These proximal vessels have 
thick walls containing a significant quantity of elastic tissue.  Due to the large radii of the 
arteries, they serve as low resistance, elastic tubes.  A portion of the cardiac stroke 
volume remains in the arteries during systole and the subsequent elastic recoil pushes the 
remaining blood to the periphery during diastole, resulting in a near-steady end-organ 
perfusion.  Blood vessels that have a high compliance value or low stiffness experience 
only small change in systolic pressure for a given change in volume.  Therefore, people 
with compliant vessels have low pulse pressures while the opposite is true for stiff 
vessels.  In brief, vascular compliance (stiffness) properties govern pressure and flow 
pulsatilites in the systemic arterial circulation. 
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 2.2 Quantitative Characterization of Arterial Mechanical Properties 
 
2.2.1 Input Impedance Spectrum 
 
The arterial system hydraulic load is the opposition to movement of blood out of 
the ventricle.  Systemic arterial input impedance spectrum (Zin) is a comprehensive and 
quantitative characterization of this hydraulic load7-12.  A typical example of aortic Zin in 
the human setting, calculated as the harmonic ratio of aortic pressure (Pao) to flow (Qao), 
is shown in Figure 1. 
SVR 
Zc 
 
Figure 1: Aortic input impedance spectrum, adapted from Nichols et al. (1977) 
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 Zin is a frequency-dependent quantity and is made up of two components, 
magnitude and phase, which describe the magnitude of hydraulic load and the phase shift 
at each frequency, respectively.  The magnitude of Zin begins with a high value at zero 
frequency.  It falls as frequency increases and oscillates before reaching a constant value 
at high frequencies.  The overall compliance of the arterial circulation is one of the 
determinants of the rate of fall of Zin magnitude.  The phase angle is zero at zero 
frequency, negative at low frequencies, and makes a transition to positive values before 
returning back to zero at high frequencies. 
Although Zin is a comprehensive characterization of arterial mechanical 
properties, it is relatively an abstract concept and a relationship, i.e., a function of 
frequency.  Therefore, arterial hydraulic load is usually separated into two components: a 
steady component and a pulsatile component. 
 
2.2.2 Steady Component of Systemic Arterial Load 
 
The steady component of systemic arterial load, commonly termed as systemic 
vascular resistance (SVR.), is identical to the magnitude of Zin at zero frequency.  As 
discussed before, SVR is the hydraulic resistance to mean blood flow, residing primarily 
in the arterioles.  This quantity is relatively easy to obtain (mean aortic pressure/mean 
aortic flow) and can be physically interpreted.  It is typically the only parameter used in 
the clinical setting to quantify arterial load. 
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 2.2.3 Pulsatile Component of Systemic Arterial Load 
 
Pulsatile load originates from the geometric and elastic properties of the vessels 
and the fluid properties of the blood flowing through it.  Unlike the steady load, pulsatile 
load cannot be quantified in terms of a single number.  For example, the information 
about the pulsatile component is located in the non-zero frequency components of Zin.  As 
mentioned above, quantitation in terms of Zin is very abstract and therefore, indices have 
been developed to characterize various aspects of pulsatile load (e.g., global arterial 
compliance, characteristic impedance, pulse wave velocity, wave reflection). 
 
2.2.3.1 Global Arterial Compliance 
 
Static vascular compliance is the steady-state change in vascular volume for a 
given change in pressure, i.e., the slope of vascular pressure/volume relationship13.  Such 
steady-state measurements are not possible under in vivo conditions and therefore, indices 
of arterial compliance are derived from simultaneous measurements of aortic pressure 
and flow data.  Global arterial compliance (AC) is one such index that is estimated either 
from the diastolic aortic pressure decay14 or by fitting instantaneous pressure and flow 
over the entire cardiac cycle15.  AC is a property of the entire systemic arterial circulation 
and is determined by elastic, geometric, and architectural (i.e., branching pattern) 
properties of systemic circulation.  As systemic arteries get less stiff, AC is expected to 
increase and vice a versa. 
 
 6 
 2.2.3.2 Characteristic Impedance 
 
As discussed before, the magnitude of Zin levels off at high frequencies; and this 
value is defined as the characteristic impedance (Zc).  Unlike AC, Zc is a local 
characterization and is determined by the geometric and elastic properties of the site at 
which pressure and flow are measured.  For an uniform cylindrical tube with purely 
elastic wall and nonviscous fluid with only axial flow, Zc is given by: (ρ indicates blood 
density; Einc, elastic modulus; h, thickness; Ri, vessel internal radius)11: 
 
242 )(
)2(
3 hRR
hRhEZ
ii
iinc
c +
+= π
ρ . (2-1) 
Zc varies directly with the elastic modulus of the artery (i.e., stiffness) and 
inversely related to its lumen size.  If Zin is calculated from the measurements of 
ascending aortic pressure and flow then Zin is a characterization of the entire systemic 
arterial circulation and Zc is the characterization of the site of measurement (i.e., 
ascending aorta). 
 
2.2.3.3 Pulse Wave Velocity 
 
Pulse wave velocity (PWV) is the speed with which pressure or flow waves travel 
along an arterial segment.  Similar to Zc, PWV is a local characterization in that it is a 
property of the vessel segment in question.  Physically, the elastic and geometric (lumen 
diameter and wall thickness) properties of the vessel segment determine PWV.  For an 
uniform elastic cylindrical tube with purely elastic wall and nonviscous fluid with only 
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 axial flow, PWV is given by: (ρ indicates blood density; Einc, elastic modulus; h, 
thickness; Ri, vessel internal radius)11: 
 2)(
)2(
3
1
hR
hRhEPWV
i
iinc
+
+= ρ . (2-2) 
As a consequence of increasing vessel wall stiffness and decreasing caliber, PWV 
increases as one moves from the heart to the peripheral circulation (Figure 2). 
 
Solid line: dog 
Broken line: human 
 
Figure 2: Regional differences in pulse wave velocity (adapted from Asmar R., 1999) 
 
PWV of a given region has been found to increase with aging, hypertension, and 
renal failure2,16 and also has been useful in determining the vascular effects of 
vasodilating drugs and antihypertensive therapies17. 
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 2.2.3.4 Wave Reflection Indices 
 
The pulsatile ejection of blood from the left ventricle results in a pressure wave 
(which is an acoustic wave) that travels towards the peripheral circulation.  Throughout 
the cardiovascular system, there are many sites where impedance mismatch occurs (e.g., 
arterial branching points and terminations at the arteriolar level).  At these sites, a fraction 
of the pressure wave is reflected back towards the heart.  The body size of the person, 
location of the heart along the long axis, and PWV determine the timing of these reflected 
waves at the ascending aorta, while the magnitude of the reflected wave is dependent on 
the magnitude of the impedance mismatch. 
Several quantitative characterizations of overall arterial wave reflection have been 
developed.  For example, global reflection coefficient, Γ, is defined as: 
 





+=Γ ZZ
ZZ
c  in
c - in
. (2-3) 
Because Zin is a complex number and a function of frequency, Γ is also a complex 
quantity that varies with frequency.  The magnitude of Γ (Γ) lies between 0 (no 
reflections) and 1 (maximum reflections) and one typically focuses on its first harmonic, 
Γ1.  Another approach for quantifying arterial wave reflections is to first decompose 
aortic pressure and flow waves into forward (i.e., traveling away from the heart) and 
backward (i.e., traveling towards the heart) waves18 and then calculate reflection index 
(RI) as the ratio of forward and backward pressure (or flow) wave amplitudes.  Wave 
reflections can significantly alter aortic pressure wave morphology.  For example, 
differences in aortic pressures between old and young subjects are illustrated in Figure 3.  
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 In the old subject, the peak of the reflected wave occurs during systole such that there is a 
secondary rise in systolic pressure.  This early return of the reflected wave is due to the 
increased PWV known to occur with aging (increased vascular stiffness).  The secondary 
rise in systolic pressure imposes an additional load on ventricular ejection and is likely to 
increase myocardial oxygen consumption.  In the younger subject, the reflected wave 
occurs during diastole causing an augmentation of aortic pressure during diastole.  This 
diastolic pressure augmentation is likely to be beneficial from the perspective of cardiac 
perfusion. 
 
 
 
Figure 3: Central pressure contours (from Asmar R., 1999) 
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 2.3 Pulsatile Arterial Load and Cardiovascular Remodeling and Risk 
 
Acute changes in pulsatile arterial load primarily affect pressure and flow wave 
morphologies10,18-21; the effects on mean pressure and flow, however, are small.  For 
example, an increase in vascular wall stiffness, a quantity that is inversely proportional to 
global arterial compliance, with all other factors held constant, shows a significant 
increase in pressure and flow pulsatilities, e.g., a greater pulse pressure with a taller and 
narrower flow pulse.  It is commonly accepted that the greater pulse pressure is related to 
an increased systolic aortic pressure, however our studies21 have shown that changes in 
diastolic aortic pressures have greater contribution to the changes in pulse pressure. 
The mean blood pressure, determined by SVR and cardiac output, is a major 
determinant of left ventricular (LV) hypertrophy22,23.  The role of pulsatile arterial load in 
this remodeling process may be more important than previously acknowledged.  From a 
vascular perspective, increased pulse pressure or cyclic wall stress (strain) has been 
postulated to accelerate the normal age related remodeling of the arterial wall (vessel 
dilation and stiffening of the wall)24,25.  In addition to its effects on cyclic wall stress 
(strain), increased flow pulsatilities result in an increase in oscillatory shear stress at the 
vascular endothelium.  It is known that endothelial shear stress is a modulator of 
endothelial function and of vascular mechanical behavior.   
Several epidemiological studies have shown that both diastolic and systolic blood 
pressures and the presence of LV hypertrophy are independent risk factors for 
cardiovascular diseases26-32.  A study by Darne et al.33 describes the relationship between 
steady and pulsatile component indices of blood pressure and cardiovascular mortality.  
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 Their longitudinal study indicated that the steady component index was a strong 
predicting factor in both males and females for all types of cardiovascular diseases, 
however the pulsatile component index in women over the age of 55 years was linked to 
mortality from coronary artery disease. 
 
2.4 Post-menopausal Women 
 
Menopause is the irreversible end of the reproductive stage in a woman’s life.  
This usually occurs around the age of 50 with menstrual cycles becoming less frequent.  
Menopause is caused primarily by ovarian failure when the ovaries fail to respond to the 
gonadotropins (sex hormones) mainly because the follicles and eggs have disappeared 
through atresia6.  Although small amounts of estrogen are still secreted into the plasma, 
largely from the alteration of adrenal androgens to estrogen, menopause is associated 
with a precipitous fall in plasma estrogen levels.  Menopause is associated with 
osteoporosis (decrease in boss mass and strength), hot flashes, night sweats, vaginal 
dryness, and increase in cardiovascular disease. 
Epidemiological studies have shown that the incidence of cardiovascular disease 
and risks are lower in pre-menopausal women compared to similar-aged men and these 
gender differences disappear in the post-menopausal state3 (Figure 4).  Studies have 
shown that women have higher levels of triglycerides, cholesterol, and, low-density 
lipoprotein cholesterol after menopause as compared to pre-menopausal women34.  These 
changes are due to a combination of the following factors: the effects of menopause 
(decrease in estrogen hormone production), weight gain, and aging.  Menopause can be 
 12 
 caused surgically.  In this case the risks of cardiovascular disease seem to increase much 
more rapidly than those seen with natural menopause. 
 
 
 
Figure 4: Prevalence of cardiovascular diseases (from AHA 2002, 
www.americanheart.org) 
 
2.5 Hormone Replacement Therapy 
 
Increasing plasma estrogen level by administering exogenous estrogen was the 
primary focus of the original hormone replacement therapy (HRT).  Although this form 
of HRT is effective in preventing menopause-associated osteoporosis and hot flashes, the 
long-term usage increases the risk of developing uterine endometrial cancer6.  It was 
found that the increased risk of endometrial cancer is virtually absent when progesterone 
 13 
 is added along with estrogen.  Thus, the current form of HRT consists of administering 
estrogen and progesterone, except for those women who have had a hysterectomy; here 
estrogen alone can be taken. 
Several studies indicate that there is a decrease of cardiovascular disease in 
women with post-menopausal HRT and increase in survival rates of women with 
coronary artery disease35.  It was argued that HRT significantly decreases mortality in 
post-menopausal women, principally through the cardio-protective ability of estrogen 
against heart disease6.  However, the most recent study36 indicates that HRT is actually 
associated with increased risk of coronary heart disease (CHD) during the first year, and 
a decreased risk during years 3 to 5.  This was a randomized, double blinded, placebo-
controlled trial of 4.1 years’ duration (HERS) and subsequent unblinded follow-up for 2.7 
years (HERS II).  It was concluded that post-menopausal HRT should not be used to 
decrease the risk of CHD in women already with CHD.  In the past, the protection of 
women using HRT against cardiovascular disease was considered to be much greater than 
the negative effect of increased cancer.  Just recently, a report37 from the Women’s 
Health Initiative decided to stop their estrogen plus progestin component post-
menopausal women trial.  After 5.2 years of follow-up, the report indicated that CHD and 
invasive breast cancer were primary adverse outcomes of the treatment.  It concluded that 
the overall health risks exceeded the benefits once believed to come from combining 
estrogen and progestin.  It is not yet clear whether alternative forms of HRT can have the 
desired cardio-protective effects to modify arterial stiffness in a long-term setting.  This 
study will illustrate the results from the two different forms of HRT used, HRT-E and 
HRT-EP. 
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 2.6 Hormone Replacement Therapy and Arterial Stiffness 
 
The exact mechanisms underlying estrogen-mediated changes in the 
cardiovascular system are not fully understood.  The mechanism by which exogenous 
estrogen usage after menopause prevents cardiovascular disease is most likely associated 
to multiple factors35.  These factors include alterations in lipid profile, endothelium-
derived relaxing factor in coronary arteries, and its vasodilatory effects. 
Arterial stiffness, quantified in terms of PWV, has been seen to increase with age 
in both men and women38-40.  Following menopause, this aging-associated increase in 
PWV in women appears to accelerate13,38.  A study of hypertensive women also found a 
rapid decrease in compliance at perimenopause and has related this to changes in 
endogenous estrogen levels2.  Thus, the loss of estrogen at menopause is one of the likely 
explanations for the increased arterial stiffness as quantified by increased PWV or 
decreased arterial compliance.  Experimental animal and human studies have shown that 
estrogen administration has a vasodilatory effect and also results in structural changes in 
large and coronary arteries41.  Estrogen has been found to cause a rapid release of nitric 
oxide in cultured endothelial cells3.  Alterations in endothelium-derived relaxing factor 
support the idea that estrogen affects vascular tone via the nitric oxide pathway.  
Endothelial nitric oxide synthase (eNOS) is stimulated by estrodial via nongenomic 
actions of estrogen receptor α (ERα)42.  Estrodial is an important agonist for endothelial 
nitric oxide synthase (eNOS) in both physiologic and pathophysiological conditions, 
especially in our case, affecting arterial stiffness in post-menopausal women receiving 
HRT43.  Local administration of estrogen causes immediate vasodilatory responses in 
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 large arteries, while actual structural changes take a longer time41.  Preliminary reports 
have indicated a reduction in arterial stiffness with short-term intravenous administration 
of estrogenic compounds in a group of post-menopausal women44. 
Long-term treatment with estrogen-containing hormonal therapy has been shown 
to partially reverse the increase in arterial stiffness and may contribute to a lowering of 
cardiovascular risk factors (e.g., incidence of myocardial ischemia) 34.  Estrogen does 
have direct effects on vascular connective tissue degradation45 and inhibition of vascular 
smooth muscle cells46.  These findings suggest that long-term estrogen administration 
should have a favorable influence on arterial stiffness via vascular remodeling.  However, 
a long-term study of post-menopausal usage of the synthetic steroid Tibolone, which is 
structurally related to norethisterone, did not alter arterial compliance, as quantified by 
aortic PWV47. 
Estrogen receptors have been discovered in the cardiovascular system of certain 
animals, baboons and rats, and also in humans, while progesterone receptors have been 
identified in the human heart and great vessels35.  Animal data have supported the 
hypothesis that estrogen targets the cardiovascular system and plays a role in regulating 
cardiovascular cell function and cardiovascular remodeling48.  A finding discussing the 
atherosclerotic coronary arteries of pre-menopausal women also supported this 
hypothesis.  This finding illustrated that there was a decrease in the number of estrogen 
receptors in smooth muscle cells in women with atherosclerosis when compared to 
similar women with no atherosclerosis49.  Post-menopausal estrogen usage in women has 
been linked to a decline in the common carotid artery wall thickness and decreasing 
occurrence of subclinical carotid stenosis when compared with those women who had 
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 never used estrogen50.  Therefore, it seems that post-menopausal estrogen usage in 
women may be beneficial in lowering the risk of cardiovascular disease. 
 
2.7 Background Summary 
 
The arterial system hydraulic load (i.e., the opposition to movement of blood out 
of the ventricle) consists of steady (i.e., SVR) and pulsatile components.  Vascular 
stiffness (elastic property) is a major determinant of the pulsatile load.  Menopause 
accelerates the age-associated increase in arterial stiffness13,38.  There is evidence that 
pulsatile arterial load plays a role in cardiovascular remodeling and may be an 
independent cardiovascular risk factor.  Finally, estrogen administration results in acute 
vasodilation and vascular remodeling in the chronic setting.  Therefore, an examination 
of the chronic effects of HRT on pulsatile arterial load, especially vascular stiffness 
aspects is a worthwhile effort.  This is precisely the goal of the present study. 
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 3.0 METHODS 
 
3.1 Study Design 
 
The present study examined the effects of chronic HRT on systemic vascular 
properties of post-menopausal women.  Thirty-five post-menopausal women were studied 
and divided into two groups: women receiving no hormone replacement therapy (control, 
n=25) and women receiving hormone replacement therapy (HRT-all, n=10).  The HRT-
all group was further subdivided into two-subgroups: women receiving estrogen alone 
(n=5, Premarin, 0.625mg/day of conjugated estrogen, HRT-E) and those women 
receiving estrogen and progesterone (n=5, Prempro, 0.625mg/day of conjugated estrogen 
+ 2.5 mg/day of medroxyprogesterone acetate, HRT-EP).  All subjects in the HRT-E 
group had previously undergone hysterectomy.  The basic demographic characteristics of 
study participants are shown in Table 1. 
 
Table 1: Subject Characteristics 
 Control 
(n = 25) 
HRT-all 
(n = 10) 
  HRT-E 
(n = 5) 
HRT-EP 
(n = 5) 
Age at study initiation 53±1 49±1 50±1 
Age at menopause 49±1 49±1 47±3 
Weight (kg) 68±3 70±3 70±5 
Height (cm) 166±2 165±1 158±3 
Maternal Race    
White 
Black 
Asian 
18 
6 
1 
3 
2 
0 
4 
1 
0 
Data are mean±SEM 
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 Noninvasive data (tonometric pressures and Doppler-based aortic blood flow 
waveforms) were collected serially at five different times: once at baseline during the 
first visit and during four subsequent visits after the initiation of the study at 19±1, 
108±5, 193±4, and 388±8 days, respectively.  None of the study participants were 
receiving HRT or any other cardiovascular medications prior to the initiation of the 
present study. 
 
3.2 Experimental Measurements 
 
All subjects were weighed and underwent noninvasive evaluations to quantify 
global (SVR, AC, and wave reflection indices) and regional (PWV) properties of systemic 
arterial circulation.  Noninvasive measurements included: (1) electrocardiogram (ECG), 
(2) brachial artery systolic, diastolic, and mean pressures by automated oscillometric 
sphygmomanometry, (3) tonometric pressure waveforms at several vascular sites 
(carotid, femoral, brachial, and radial) using pressure sensors designed for non-invasive 
recording of pulse pressure wave contours, (4) ascending aortic blood velocity (flow) 
waveforms using Doppler ultrasound.  All studies were performed in the left lateral 
decubitus position, and data were acquired after the patient had been resting for ten 
minutes. 
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 3.2.1 Noninvasive Measurement of Pressure Waveform 
 
It is possible to record high-fidelity arterial pressure waveform noninvasively at 
various locations using applanation tonometry51-57.  A miniature strain gauge transducer, 
mounted in a hand-held, pencil-probe (SPT-301, Millar Instruments), was used to record 
pressures from right carotid, right brachial, and left femoral sites.  All analog pressure 
data was digitized on-line at 1000 Hz using a portable PC-based data acquisition system.  
An automated, wrist-worn tonometer was used to record pressure waveform data from 
the right radial site (Pilot 9200, Colin Medical Instruments Corp.).  Pressure waveforms 
were calibrated using brachial artery blood pressures determined with an oscillometric 
sphygmomanometer, with the pressure cuff located on the left arm (Pilot 9200, Colin 
Medical Instruments Corp.).  The brachial artery pressure waveform was calibrated first 
by assigning the systolic and diastolic brachial pressures to the maximum and minimum 
of the waveform, respectively.  The mean arterial pressure (MAP) was computed from the 
calibrated brachial artery pressure waveform and assumed to be the same for all other 
locations (i.e., carotid, femoral, and radial).  One more calibration point is needed in 
order to fully calibrate pressure waveforms at these other locations.  It was assumed that 
that diastolic pressures were the same at different locations, an assumption that is 
supported by experimental data56,58.  Simultaneously recorded pairs of pressure 
waveforms (carotid and femoral; brachial and radial) are illustrated in Figure 5. 
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Figure 5: Noninvasive and simultaneous measurements of pressure waveforms at two 
sites using tonometers.  A: carotid and femoral; B: brachial and radial.  ∆T = time-delay 
between the two pressure waveforms. 
 
3.2.2 Noninvasive Measurement of Ascending Aortic Flow Waveform  
 
Noninvasive instantaneous ascending aortic flow data were obtained from the 
measurements of aortic blood velocity and left ventricular outflow tract diameter (DLVOT) 
(Figure 6).  Aortic blood velocity was recorded from the cardiac apex using a two-
dimensionally guided pulsed wave Doppler (Hewlett Packard, SONOS-5000, 2.5 Mhz 
phased-array & 7.5 or 12 Mhz linear).  The instantaneous velocity signals were recorded 
on paper and then digitized using custom-built software.  The instantaneous volumetric 
blood flow was calculated as the product of measured instantaneous blood velocity and 
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 cross-sectional area (= πD2LVOT/4).  This calculation assumes a flat velocity profile and 
negligible variation in DLVOT over the cardiac cycle at the ascending aorta.  A typical 
example of simultaneous ECG, carotid pressure waveform, and echocardiographic view 
of LV outflow tract diameter is illustrated in Figure 6. 
 
 
 
Figure 6: 2D echocardiographic view of LV outflow tract diameter (top). Simultaneous 
electrocardiogram (ECG), carotid pressure (CPT), and aortic flow velocity (CW Doppler) 
tracings 
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 3.3 Calculations of Derived Variables 
 
3.3.1 Global Systemic Arterial Mechanical Properties 
 
Aortic input impedance spectrum (Zin).  As discussed before Zin is a 
comprehensive characterization of the mechanical properties of the entire systemic 
arterial circulation.  Zin was calculated from the measured aortic pressure [Pao(t)] and 
flow [Qao(t)] waveforms using standard harmonic analysis techniques12.  Since the carotid 
pressure waveform was used as a proxy for ascending aortic pressure waveform, the 
calculations should be considered an estimate of the true aortic input impedance.  SVR 
was calculated as being Zin at zero Hz (which is identical to MAP divided by CO), Zc was 
calculated from the average of the Zin magnitudes over 4-12 Hz.  Those frequencies with 
flow magnitudes smaller than 5% of the first harmonic was excluded from this averaging 
process.  This eliminates impedance values that are due to insufficient energy in the flow 
harmonic, which can cause estimation errors. 
Global arterial compliance (AC).  AC, a quantity that is inversely proportional to 
arterial stiffness, was estimated from the diastolic decay of the aortic pressure waveform 
by the area method11,14. 
 
)( 21 PPSVR
AAC d−= , (3-1) 
 
where P1 and P2 are pressures at the beginning (i.e., peak pressure following the dicrotic 
notch) and the end (end diastolic pressure) of the diastolic decay region and Ad is the area 
underneath the diastolic portion of the pressure waveform (Figure 7).  This estimation 
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 procedure assumes pressure-independent compliance, a reasonable assumption when 
comparing compliance data between groups with small pressure differences.  However 
when pressure differences are large, a pressure-dependent compliance model must be 
used for calculating AC.  This was not necessary in the present study.  Our expectation 
was that AC would increase in patients receiving HRT. 
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Figure 7: Calculation of global arterial compliance using the area method 
 
Global arterial wave reflections.  Two indices were calculated for this purpose: 
reflection index (RI), calculated as the ratio of the backward and forward pressure wave 
peak-to-peak amplitudes18, and the magnitude of the first harmonic of global reflection 
coefficient (Γ1), derived from the estimated input impedance spectrum and aortic 
characteristic impedance12.   
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 Hydraulic power.  Instantaneous pressure and flow data were used to calculate 
total (Wtot), steady (Wstd = MAP*CO), and oscillatory (Wosc = Wtot - Wstd) power12: 
 ∫= Ttot dttQtPTW 0 )()(
1 , (3-2) 
where T is the cardiac cycle duration.  Wosc is power that is wasted during pulsations; the 
ratio of Wosc and Wtot was used as a measurement of the inefficiency of the LV-arterial 
coupling.  A Fortran program was developed previously by Dr. Shroff in order to 
calculate all of the quantities from the digitized pressure-flow waveforms. 
 
3.3.2 Regional Arterial Mechanical Properties 
 
Pulse wave velocity (PWV).  PWV was calculated from the simultaneous 
measurements of pressure waveforms at two sites (e.g., carotid and femoral; brachial and 
radial) and distance between the sites (Figure 5).  The time delays between carotid and 
femoral (∆TC-F) and brachial and radial (∆TB-R) pressure waveforms were computed using 
a computerized algorithm (intersecting tangent method) that was previously created59.  
Three physical distances were measured by following the typical vascular pathways on 
the body surface: heart (i.e., aortic valve plane identified by echocardiography) to right 
carotid (DH-C), heart to left femoral (DH-F), and right brachial to right radial (DB-R).  
Carotid-to-femoral (PWVC-F) and brachial-to radial (PWVB-R) PWVs were calculated as 
follows. 
 
RB
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−=        , . (3-3) 
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 Our expectation was that PWV would decrease (indicating reduced arterial 
stiffness or increased compliance) in patients receiving HRT.  Quantification of PWVC-F 
and PWVB-R would allow for monitoring regional vascular stiffness changes, the former 
representing stiffness of large central vessels and the latter representing stiffness of 
smaller peripheral vessels. 
 
3.4 Statistical Analysis 
 
All statistical analyses were performed using a PC-based software (GB-Stat for 
Windows).  Data were normalized to the first visit representing baseline values.  For each 
parameter, a two-way ANOVA (factor 1: therapy status, control and HRT-all or control, 
HRT-E, and HRT-EP; factor 2: time, five visits) with repeated measures on factor-2 was 
used to analyze data.  When necessary, post-hoc analysis was performed to further 
characterize the observed differences.  Specifically, temporal changes within each 
therapy group were analyzed by comparing the normalized values during Visits 2-5 
versus 1 (which is the normalized value at baseline or Visit 1) using the Dunnett’s test.  
In addition, differences between the control group and the HRT groups at matched time 
points (i.e., at Visits 2, 3, 4, and 5) were examined using pairwise comparisons (8 
comparisons in our case), with the P value adjusted for multiple comparisons (Bonferroni 
correction).  A P value of less than 0.05 for the set of all comparisons was taken to 
indicate statistically significant differences.  Data are presented as mean±SEM. 
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 4.0 RESULTS 
 
4.1 Hemodynamic Variables 
 
Group-averaged hemodynamic data are presented in Table 2-6.  Graphical 
representations of relative changes in these hemodynamic variables are illustrated in 
Figure 8-14.  It should be noted that although a straight line connects successive 
measured data points, this should not be taken to represent actual temporal changes 
between measurement points.  Heart rate (HR), stroke volume (SV), and cardiac output 
(CO) did not change significantly in the control group throughout the study period 
(Figure 8-10).  This was also true for both HRT groups, except for a small decrease in HR 
at Visits 3 and 4 for the HRT-E group (Figure 8) and an increase in CO at Visit 3 in the 
HRT-EP group (Figure 10).  Mean arterial pressure (MAP) decreased over time in both 
the control and the two HRT groups, reaching statistical significance at the fifth visit 
(Figure 11).  Carotid peak systolic (Ps-carotid) and minimum diastolic pressures (Pd) tended 
to decrease over time as well, but these changes did not reach statistical significance 
(Figure 12 and 14). 
 
Table 2: General Hemodynamics, Visit 1 
 Control HRT-all HRT-E HRT-EP 
HR, bpm 75±3 78±3 84±2 73±4 
CO, L/min 4.9±0.2 5.0±0.2 4.9±.3 5.0±0.4 
SV, mL 66±3 64±2 59±3 68±3 
MAP, mmHg 87±1 88±2 87±3 88±2 
Ps-carotid, mmHg 110±2 109±3 109±5 109±3 
Pd, mmHg 70±1 70±1 69±1 70±2 
Ps-brachial, mmHg 123±2 121±3 120±5 122±2 
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 Table 3: General Hemodynamics, Visit 2 
 Control HRT-all HRT-E HRT-EP 
HR, bpm 73±2 72±3 76±3 68±4 
CO, L/min 4.9±0.2 4.7±0.1 4.6±0.1 4.9±0.2 
SV, mL 69±3 67±4 60±2 73±6 
MAP, mmHg 84±2 83±2 85±3 81±2 
Ps-carotid, mmHg 104±2 106±3 108±5 103±2 
Pd, mmHg 68±2 65±2 66±3 64±3 
Ps-brachial, mmHg 118±2 116±3 118±5 114±3 
 
Table 4: General Hemodynamics, Visit 3 
 Control HRT-all HRT-E HRT-EP 
HR, bpm 71±2 76±2 73±3 79±4 
CO, L/min 4.8±0.2 5.2±0.3 4.6±0.1 6.0±0.5 
SV, mL 67±3 68±3 62±1 75±5 
MAP, mmHg 85±2 85±2 85±2 84±3 
Ps-carotid, mmHg 106±2 106±3 109±5 103±4 
Pd, mmHg 68±2 67±2 67±1 67±3 
Ps-brachial, mmHg 120±2 119±3 117±4 121±4 
 
Table 5: General Hemodynamics, Visit 4 
 Control HRT-all HRT-E HRT-EP 
HR, bpm 72±3 73±3 73±2 74±5 
CO, L/min 4.8±0.2 5.0±0.3 4.6±0.5 5.3±0.3 
SV, mL 68±3 68±4 64±7 72±3 
MAP, mmHg 83±2 83±1 82±1 83±2 
Ps-carotid, mmHg 105±3 103±3 105±5 102±3 
Pd, mmHg 65±2 65±1 65±2 66±2 
Ps-brachial, mmHg 116±2 118±2 116±5 119±2 
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 Table 6: General Hemodynamics, Visit 5 
 Control HRT-all HRT-E HRT-EP 
HR, bpm 72±3 74±2 78±3 70±2 
CO, L/min 4.9±0.2 4.8±0.2 4.9±0.4 4.7±0.1 
SV, mL 68±3 65±2 62±3 68±3 
MAP, mmHg 83±2 82±1 84±3 81±2 
Ps-carotid, mmHg 103±3 103±1 103±1 103±3 
Pd, mmHg 66±0 65±2 68±4 62±2 
Ps-brachial, mmHg 118±2 113±3 121±1 113±3 
 
HR indicates heart rate; CO, cardiac output; SV, stroke volume; Ps-carotid, carotid peak 
systolic pressure; Pd, carotid or brachial minimum diastolic pressure; Ps-brachial, brachial 
peak systolic pressure.  Data are mean±SEM. 
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Figure 8: Normalized heart rate responses 
All figures are normalized to the first visit (baseline) of each respective group. 
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Figure 9: Normalized stroke volume responses 
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Figure 10: Normalized cardiac output responses 
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Figure 11: Normalized mean arterial pressure responses 
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Figure 13: Normalized minimum diastolic blood pressure responses 
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Figure 12: Normalized carotid (aortic) peak systolic blood pressure responses 
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 4.2 Global Systemic Arterial Mechanical Properties 
 
We first examined the input impedance spectrum (Zin) because it provides a 
comprehensive characterization of global systemic arterial mechanical properties.  The 
magnitude of Zin as a function of frequency for the control and two HRT groups are 
illustrated in Figure 14-17.  For the sake of clarity, data from only three visits are shown 
in each of these figures.  There are no clear changes in the magnitude of Zin over time for 
the control and HRT-EP groups.  The magnitude of Zin appears to fall over time for the 
HRT-E group, especially at low frequencies (i.e., below 3 Hz).  We will now examine the 
various aspects of Zin (e.g., SVR, AC, Zc, Z1, reflection indices) in more detail. 
 
Figure 14: Magnitude of Zin for the control group at three selected visits 
|Z
 (d
y
s/
5 )
Frequency (Hz)
in
|
ne
.
cm
0
200
1000
1200
1400
1600
1800
Visit 1
Visit 3
0 2 4 6 8 10 12 14 16 18
Visit 5
Control
 33 
  34 
 
Figure 16: Magnitude of Zin for the HRT-EP group at three selected visits 
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Figure 15: Magnitude of Zin for the HRT-E group at three selected visits 
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 Group-averaged data for global systemic arterial characterization are presented in 
Table 7-11.  Graphical representations of relative changes in selected systemic arterial 
mechanical properties are illustrated in Figure 17 and 18. 
Total systemic vascular resistance (SVR).  Overall, SVR did not change 
significantly in either the control or the HRT groups (Figure 17), except for one isolated 
decrease in SVR at Visit 3 for the HRT-EP group (Figure 17). 
Global arterial compliance (AC).  AC was unchanged for the control and HRT-EP 
groups.  In contrast, AC increased in the HRT-E group, reaching statistical significance at 
the fifth visit (Figure 18). 
First harmonic of input impedance spectrum (Z1) and reflection indices.  Z1 and 
both indices of global arterial reflections did
or the HRT g
Hydraulic power.  Wtot, Wstd, and Wosc indices of hydraulic power of the efficiency 
of the left ventricle did not change significantly in either the control or the HRT groups.   
 
Table 7: Global Systemic Arterial Characterization, Visit 1 
 NO HRT HRT HRT-E HRT-EP 
 not change significantly in either the control 
roups.   
SVR, dyne.s/cm5 1493±67 1440±67 1440±107 1440±93 
AC, mL/mmHg 1.81±0.13 1.58±0.12 1.54±0.25 1.61±0.06 
Z1, dyne.s/cm5 155±14 150±15 152±30 148±13 
RI 0.47±0.02 0.47±0.02 0.45±0.03 0.48±0.02 
Γ1 0.43±0.02 0.44±0.02 0.45±0.04 0.44±0.03 
Wtot, mW 1069±69 1123±48 1115±59 1130±84 
Wstd, mW 912±59 967±44 957±51 978±78 
Wosc, mW 156±15 155±12 158±25 152±8 
%Wosc 15% 14% 14% 13% 
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 Table 8: Global Systemic Arterial Characterization, Visit 2 
 NO HRT HRT HRT-E HRT-EP 
AC, mL/mmHg 1.86±0.13 1.65±0.13 1
SVR, dyne.s/cm5 1426±67 1413±53 1493±80 1333±53 
.47±0.17 1.83±0.16 
Z1, dyne.s/cm5 139±9 160±15 170±23 151±21 
RI 0.47±0.02 0.50±0.01 0.50±0.01 0.50±0.02 
Γ1 0.45±0.02 0.44±0.02 0.46±0.01 0.42±0.03 
W , mW ± ± ± ±tot 1071 43 1036 39 1022 53 1050 63 
Wstd, mW 923±37 872±30 863±30 880±56 
Wosc, mW 148±10 164±19 159±28 170±28 
%Wosc 14% 16% 16% 16% 
 
Table 9: Global Systemic Arterial Characterization, Visit 3 
 NO HRT HRT HRT-E HRT-EP 
SVR, dyne.s/cm5 1480±67 1346±80 1506±53 1160±133 
Z1, dyne.s/cm5 148±10 147±18 172±27 115±9 
Γ  
AC, mL/mmHg 1.77±0.10 1.35±0.10 1.47±0.14 1.92±0.11 
RI 0.48±0.02 0.46±0.02 0.47±0.02 0.45±0.04 
1 0.46±0.02 0.43±0.02 0.45±0.02 0.40±0.03 
Wtot, m 46 1133W 1048± ±67 1021±40 1273±113 
±
Wosc, mW 149±10 162±12 157±20 167±15 
Wstd, mW 900±40 971 60 864±30 1106±98 
%Wosc 14% 14% 15% 13% 
 
 NO 
Table 10: Global Systemic Arterial Characterization, Visit 4 
HRT HRT HRT-E HRT-EP 
SVR, dyne.s/cm5 1413±53 1360±93 1493±173 1266±53 
AC, mL/mmHg 1.72±0.15 1.92±0.25 1.88±0.47 1.95±0.29 
Z1, dyne.s/cm5 153±9 145±17 168±35 127±14 
RI 0.49±0.02 0.44±0.02 0.46±0.03 0.43±0.02 
Γ1 0.45±0.02 0.40±0.02 0.41±0.03 0.40±0.03 
Wtot, mW 1059±57 1072±63 994±97 1135±81 
Wstd, mW 899±45 913±57 839±88 972±72 
Wosc, mW 160±15 160±16 155±26 163±22 
%Wosc 15% 15% 16% 14% 
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 Table 11: Global Systemic Arterial Characterization, Visit 5 
 
 NO HRT HRT HRT-E HRT-EP 
SVR, dyne.s/cm5 1426±67 1386±67 1400±133 1373±53 
AC, mL/mmHg 1  1  1  1  .90±0.16 .67±0.09 .82±0.13 .52±0.07
Z1, dyne.s/cm5 147±12 143±10 134±14 153±13 
RI 0.48±0.02 0.49±0.02 0.48±0.03 0.50±0.02 
Γ1 0.45±0.02 0.46±0.02 0.45+0.03 0.47+0.04 
Wtot, mW 1045±60 1022±40 1044±77 1001±35 
Wstd, mW 893±50 876±32 902±61 851±23 
Wosc, mW 1  1  1  1  52±14 46±15 42±28 50±17
%Wosc 15% 17% 14% 15% 
SVR indicates total systemic vascular resistance; AC, global arterial compliance; Z1, 
modulus of firs RI, reflection 
index; Γ1, magnitude of the first harmonic of the global reflection coefficient 
pectrum; Wtot, total p , steady power; Wosc, oscillatory power; % nt 
  Da n±SEM
t (fundamental) harmonic of the input impedance spectrum; 
s ower; Wstd Wosc, perce
oscillatory power. ta are mea . 
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Figure 17: Normalized total systemic vascular resistance responses 
 
Figure 18: Normalized global arterial compliance responses 
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 4.3 Regional Arterial Mechanical Properties 
 
Group averaged PWV data are presented in Table 12-16 and graphical 
representations of relative changes in PWV data are illustrated in Figure 19 and 20. 
Carotid-to-femoral pulse wave velocity (PWVC-F).  For the control group, PWVC-F 
seemed to increase over time, with a statistical significance observed at the fourth visit (~ 
6 months).  This is consistent with the age-associated increase in vascular stiffness.  This 
age-associated increase in PWVC-F was significantly blunted in the HRT-E group during 
the early phases of the therapy (Figure 19).  However, estrogen-mediated decrease in 
PWVC-F seemed to wane at the late stage of therapy (> 1 year).  The addition of 
progesterone (HRT-EP group) mitigated the estrogen-mediated decrease in PWVC-F 
during the early phases; however, the late responses for the two groups (HRT-E and 
HRT-EP) were similar (Figure 19). 
Brachial-to-radial pulse wave velocity (PWVB-R).  No significant temporal 
changes in PWVB-R were observed in the control group.  In contrast, PWVB-R began to 
decrease after the initiation of HRT-E, reaching statistical significance at the fourth visit 
(~ 6 months).  However, this trend appeared to reverse during the late stages of the 
therapy (Figure 20).  The addition of progesterone (HRT-EP group) significantly 
mitigated the estrogen-mediated decrease in PWVB-R (Figure 20). 
Aortic characteristic impedance (Zc).  There were no significant changes in Zc 
over time for the control and both HRT groups (Table 12-16). 
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 Table 12: Regional Arterial Mechanical Characterization, Visit 1 
 Control HRT-all HRT-E HRT-EP 
PWVC-F, cm/s 680±32 704±40 710±31 732±53 
PWVB-R, cm/s 798±50 801±39 849±69 754±32 
c
 
Z , dyne.s/cm5 113±13 105±12 104±24 106±3 
Table 13: Regional Arterial Mechanical Characterization, Visit 2 
 Control HRT-all HRT-E HRT-EP 
PWVC-F, cm/s 719±40 663±48 613±47 726±88 
PWV , cm/s 684±45 718±64 669±61 779±127 B-R
Zc, dyne.s/cm  96±6 111±10 110±13 112±16 
PWVC-F, cm/s 707±50 708±32 633±29 778±35 
Zc, dyne.s/cm5 100±6 107±8 113±10 99±14 
5
 
Table 14: Regional Arterial Mechanical Characterization, Visit 3 
 Control HRT-all HRT-E HRT-EP 
PWVB-R, cm/s 725±29 768±53 696±85 857±11 
 
Table 15: Regional Arterial Mechanical Characterization, Visit 4 
 Control HRT-all HRT-E HRT-EP 
PWVC-F, cm/s 781±43 667±26 650±36 680±40 
B-R 816 48 755 73 605 92 875 79 
Z , dyne.s/cm5 107±8 118±15 111±18 124±23 c
 
Table 16: Regional Arterial Mechanical Characterization, Visit 5 
 Control HRT-all HRT-E HRT-EP 
PWV , cm/s 
PWV , cm/s ± ± ± ±
C-F 736±69 752±57 721±98 780±59 
PWVB-R, cm/s 848±106 808±83 755±131 878±102 
5
PWVC-F indicates carotid-to-femoral pulse wave velocity; PWVB-R brachial-to-radial pulse 
wave velocity; Zc, aortic characteristic impedance.  Data are mean±SEM. 
Zc, dyne.s/cm  108±10 98±8 86±11 110±12 
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Days
Figure 19: Normalized carotid-to-femoral PWV responses 
 
Figure 20: Normalized brachial-to-radial PWV responses 
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 5.0 DISCUSSION 
 
5.1 Main Observations 
 
 The goal of this present study was to examine the long-term effects of hormone 
replacement therapy on systemic arterial hemodynamics and mechanical properties, 
especially arterial stiffness, in post-menopausal women.  This was accomplished by 
studying thirty-five post-menopausal women over a period of approximately one year. 
The main result of the present study is that chronic HRT reduces vascular 
stiffness, as indicated by an increase in AC and a decrease in PWV, only in the group 
receiving estrogen alone (HRT-E).  When investigating hemodynamic responses to 
chronic HRT, no significant 
decreases in MAP were seen at the fifth visit during the study period.  Systolic and 
diastolic pressures also tended to decrease during the study, but no statistical significance 
was reached.  Thus, the cardio-protective effects of HRT (at least from the arterial 
stiffness perspective) seem to be limited to estrogen use alone.   
 
5.2 Methodological Considerations and Limitations 
 
Noninvasively recorded pressure waveforms are calibrated using blood pressures 
determined with an oscillometric sphygmomanometer at the brachial artery.  This 
calibration procedure was based on two assumptions:  mean and diastolic pressures are 
equal at all sites.  Because viscous losses are minimal, mean pressure is assumed to be the 
significant changes were seen in HR, SV and CO, but 
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 same at all sites, especially in h ructive vascular disease.  It 
as reasonable to assume that diastolic pressures at different locations are relatively 
similar56,58.  This issue of calib arotid pressure waveform 
ecause global mechanical property (e.g., Zin, AC, SVR) calculations required these 
w) 
wavefo
.  Although DLVOT varies 
omewhat over the cardiac cycle, this change is quite small, especially at the aortic valve 
plane.  There i er cending aortic 
ite61,62. 
ealthy women with no obst
w
ration was relevant only for the c
b
calibrated pressure values.  However, PWV only required simultaneous waveform 
measurements; pressure calibration was not necessary. 
The calculation of systemic arterial global mechanical properties requires 
simultaneous measurements of ascending aortic pressure and blood velocity (flo
rms.  The carotid pressure waveform was used as a surrogate for the ascending 
aortic pressure waveform.  These two waveform morphologies are reasonably similar, 
except for a slight time-delay in the carotid pressure waveform54,56,60.  This time delay 
was corrected by aligning the carotid pressure upstroke with the rapid rise of the Doppler 
velocity signal. 
Two assumptions were made to obtain volumetric flow from ascending aortic 
blood velocity measurements: a flat velocity profile in the radial direction and constant 
cross-sectional area or diameter (DLVOT) over the cardiac cycle61
s
s exp imental evidence for a flat velocity profile at the as
s
The calculation of PWV requires the measurement of two quantities: the time 
delay between simultaneously measured pressure waveforms at two sites and the distance 
between these two sites.  We had to identify the minimum (or foot) of the pressure 
waveform to obtain the time delay.  This can be problematic because the noninvasively 
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 recorded waveforms sometimes do not have a sharp minimum.  To some extent, this 
problem is minimized by the intersecting tangent method used to identify the location of 
the pressure minimum59.  Because blood velocity waveforms generally have a sharper 
upstroke, an alternative is to use simultaneously measured blood velocity waveforms at 
two sites to obtain the time delay.  A typical pathway along the body surface was used to 
obtain the distance measurement between two sites.  It is clear that potential measurement 
inaccur
r inability to find statistically significant differences may be a result of 
the sm
acies in this variable affect the absolute values of PWV.  However, distances were 
measured only once for each subject (usually during the first visit) and this single set of 
values were used to calculate PWV at all times for a given subject.  Thus, although the 
absolute PWV values may be questionable, the relative changes over time are valid.   
The number of subjects in the HRT-all group is small (n=10), especially when 
one subdivides them into two groups (estrogen alone and estrogen + progesterone; n=5 in 
each group).  Ou
all number of subjects (i.e., low power).  For example, although there was a clear 
trend for the carotid-to-femoral PWV to decrease, this did not reach statistical 
significance (Figure 19).  Clearly, more subjects are necessary to address this issue. 
 
5.3 General Hemodynamics 
 
In general, HR, SV, and CO did not change significantly in either the control or 
HRT groups throughout the study period.  West el al63 have reported similar results in 
post-menopausal women receiving transdermal estradiol and oral progesterone for six 
months.  However, Kamali et al64 reported that SV and CO increased in perimenopausal 
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 women receiving HRT (daily estradiol and intermittent norethindrone) after 5 weeks and 
these increases were maintained at 21 weeks.  MAP decreased slightly over time in both 
control and HRT groups, reaching statistical significance at the fifth visit (Figure 11).  
However this decrease was small (~5%).  Systolic and diastolic blood pressures tended to 
decrease over time as well, but these changes did not reach statistical significance (Figure 
12 and 14).  Other studies have reported essentially similar results regarding MAP2,63 and 
systolic and diastolic blood pressures65,66.  Overall, chronic HRT (HRT-E or HRT-EP) 
seems to have either no effects or only modest effects on general hemodynamic variables. 
 
5.4 Systemic Vascular Global Mechanical Properties 
 
VR did not change significantly over time in the control and HRT-E groups.  
Although a transient decre the HRT-EP group, it 
eturned to the baseline value at the end of the study (> 1 year).  Similar early decrease in 
SVR w
Although Zin is a comprehensive characterization of arterial mechanical 
properties, it is a relatively abstract quantification.  No significant changes in Zin were 
seen over time in the control group, while small decreases in the magnitude of Z1 were 
seen in the HRT-E group, consistent with the possibility of increased global arterial 
compliance. 
S
ase in SVR was noted early on in 
r
ith combined estrogen and progesterone treatment has also been reported by other 
studies63,64,66. 
AC was unchanged for the control subjects and tended to increase in the HRT-EP 
group, although this increase did not reach statistical significance.  In contrast, AC 
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 increased for the HRT-E group starting from the third visit and later reaching statistical 
significance at the fifth visit (Figure 18).  Thus, it appears that the estrogen-mediated 
increase in vascular compliance (or reduction in stiffness) is a gradual process, requiring 
at least 3-6 months of treatment for a significant change.  Although AC seems to increase 
in the HRT-EP group early on (e.g., at 200 days, Figure 18), the addition of progesterone 
completely abolishes the estrogen-mediated increase in AC at later stages (e.g., > 1 year, 
Figure 18).  We could not find any previous studies examining HRT-induced changes in 
AC in post-menopausal women. 
Chronic HRT did not affect global wave reflections as indicated by unchanged 
reflection inde d m ent (Table 7-
1).  In contrast, we had previously observed reduced wave reflections during the third 
trimest
ising that the steady power was unchanged (Table 7-11).  The observation 
that osc
x an agnitude of the first harmonic of reflection coeffici
1
er of pregnancy wherein increased AC was accompanied by decreased SVR.  
Therefore, it is likely that changes in SVR may have a greater effect on global wave 
reflections than the effects of changes in AC. 
Given that there were no significant changes in CO and MAP with chronic HRT, 
it is not surpr
illatory power and percent oscillatory power did not change (Table 7-11) implies 
that chronic HRT did not have any adverse effects on ventricular-vascular arterial 
coupling from the perspective of energy wasted in pressure and flow pulsations. 
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 5.5 Regional Vascular Mechanical Properties 
 
Carotid-to-femoral (PWVC-F) and brachial-to-radial (PWVB-R) PWV were 
quantified in the present study as indices of regional vascular stiffness.  The 
characterization of these two arterial segments allowed us to examine the effects of 
chronic HRT on larger central (PWVC-F) and smaller peripheral (PWVB-R) vessels. 
PWVC-F increased over time for control subjects (Figure 19), an observation that is 
consistent with age-associated increase in vascular stiffness16.  Although chronic HRT-E 
did not
s with respect to the differential effects of 
HRT-E
ure 20), 
indicating that the age-associated increase in vascular stiffness at the peripheral site is 
minimal over the observation period (~ 1 year).  Chronic HRT-E significantly decreased 
brachial-to-radial stiffness as indicated by the decrease in PWVB-R (Figure 20).  However, 
the inclusion of progesterone (HRT-EP group) completely eliminated the estrogen-
 significantly change PWVC-F over time with respect to its own baseline value, 
there was a significant mitigation of the age-associated increase in PWVC-F seen in the 
control subjects, especially at Visits 2, 3, and 4 (Figure 19).  Although this mitigation of 
age-associated increase in PWVC-F was also seen in the HRT-EP group, this effect was 
less pronounced during the early phases of the therapy (Visits 2 and 3, Figure 19).  
Scuteri et al65 have reported identical finding
 and HRT-EP on PWVC-F.  A decrease in PWVC-F in post-menopausal women on 
chronic HRT (some estrogen and some estrogen + progesterone) was also observed by 
Rajkumar et al2.  However they did not provide data separated according to the type of 
HRT (estrogen vs. estrogen + progesterone).   
PWVB-R did not change significantly over time for control subjects (Fig
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 mediated decrease rac n the same study 
y Rajkumar et al2 mentioned above, a decrease in femoral-to-dorsal pedis artery PWV 
was ob
 the present study for two reasons.  First, 
MAP w
 in b hial-to-radial arterial stiffness (Figure 20).  I
b
served; although this did not reach statistical significance.  This failure of 
statistically significant decrease in peripheral vascular stiffness may be related to the 
mixing of different HRTs (estrogen and estrogen + progesterone) and/or the site of the 
peripheral arterial segment. 
 
5.6 Mechanisms Underlying HRT-Induced Vascular Stiffness Changes 
 
Global arterial compliance (AC) and pulse wave velocity (PWV) data were used to 
draw inferences regarding changes in vascular stiffness.  Specifically, increased AC 
and/or decreased PWV were taken to imply reduced vascular stiffness and vice a versa.  
Potential mechanisms for increased AC and/or reduced PWV can be divided into three 
categories: (1) passive changes in vessels wall properties (stiffness) secondary to reduced 
distending pressure, (2) reduced smooth muscle tone, and (3) vascular wall remodeling. 
The stress-strain relationship of the vessel wall material is typically nonlinear, 
resulting in distending pressure-dependent changes in vascular mechanical properties67.  
It is unlikely that this factor played a role in
as reduced in both the control and HRT groups to the same extent.  Second, the 
magnitude of this reduction was small (~ 5 mmHg for MAP and ~ 4 mmHg for aortic 
diastolic pressure).  Based on the results of Carroll et al58, this degree of reduction in 
distending pressure cannot totally account for the observed HRT-E-induced decrease in 
PWV. 
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 It has been reported that acute administration of estrogen can cause vasodilation, 
mediated by the release of nitric oxide from vascular endothelial cells42,43.  The release of 
nitric oxide reduces vascular smooth muscle tone3.  In addition, Rajkumar et al2 
discussed the idea that vasodilation causes the transfer of vascular wall stress from the 
collagen fibers to the more distensible elastin fibers, allowing the vasculature to be more 
compliant.  Thus, the reduction in smooth muscle tone may be the one of the mechanisms 
underlying the observed reductions in vascular stiffness with chronic HRT-E. 
wall 
eometric properties and vessel wall composition), Westendorp et al41 reported a slight 
increas
e 
are hop
e the potential confounding effects of this factor. 
Regarding vascular remodeling (i.e., changes in vascular lumen and 
g
e in common carotid artery lumen diameter with chronic HRT (estrogen + 
progesterone).  In vitro and animal studies have demonstrated that estrogen decreases 
collagen production and collagen/elastin ratio68,69, decreases smooth muscle migration 
and proliferation70,71, and accelerates endothelial cell growth72,73.  Estrogen usage after 
menopause can also cause alterations in lipid profile: increases in high-density 
lipoproteins and decreases in low-density lipoproteins35,74.  These changes in lipid profil
eful in decreasing the development of atherosclerosis and associated vascular wall 
remodeling.  Thus, vascular remodeling may also play a role in HRT-E-induced 
reductions in vascular stiffness.  However, data regarding chronic HRT-induced vascular 
geometric and compositional remodeling in the human setting are limited. 
Age and physical training are known to affect AC75.  There were no differences in 
age among the various groups.  However, we do not have any information regarding 
physical fitness and activity of our study participants.  Therefore, it is not possible to 
evaluat
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 The main observation of the present study is that the inclusion of progesterone in 
HRT abolishes the estrogen-mediated decrease in vascular stiffness.  Previous studies 
have shown chronic estrogen administration enhances endothelial-mediated vasodilation 
and progesterone inhibits this estrogen-mediated enhancement76-79.  Although the exact 
mechanisms for the counteracting effects of progesterone are not clearly understood, 
possible causes may include downregulation of estrogen receptors and androgenic 
properties of progesterone (e.g., testosterone derivatives can exert vasoconstrictor 
influen
ogen alone in 
10,739
t cardiovascular risk factor (see 
ces, including decreases in prostacyclin).  It should be noted that not all studies 
support the notion of progesterone-mediated counteracting effects on endothelial 
function80,81. 
 
5.7 HRT and Cardiovascular Risk 
 
Earlier studies had suggested that chronic HRT is associated with certain cardio-
protective effects.  However, the most recent double blinded, randomized, placebo-
controlled study (16,608 post-menopausal women with intact uterus) indicated that 
chronic HRT (estrogen + progesterone) was actually associated with an increased 
incidence of coronary heart disease, stroke, breast cancer, and pulmonary embolism37.  A 
parallel study is examining the effects of chronic administration of estr
 women who have had a hysterectomy.  At present, the balance of overall risks and 
benefits of estrogen-alone therapy remains uncertain.  Our study indicates that the 
reduction in systemic arterial stiffness was limited to the estrogen alone group.  If one 
accepts that increased vascular stiffness is an independen
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 Section
he present study indicates chronic HRT in post-menopausal women is associated 
with reduced vascular st ss V) only when estrogen 
is used.  Both reduced smooth muscle tone and vascular remodeling may be responsible 
for this
 2.3) then estrogen alone therapy in post-menopausal women can conceivably be 
cardio-protective.  However, given that estrogen is known to cause augmented cell 
proliferation leading to an increased incidence of endometrial carcinoma, estrogen alone 
therapy is limited to women who have had hysterectomy.  It is possible that other 
estrogen preparations or alternative vasorelaxing agents may have the desirable effects on 
vascular stiffness properties without the risk of augmented cell proliferation.  Further 
work is needed to examine this possibility. 
 
5.8 Conclusions 
 
T
iffne (i.e., increased AC and reduced PW
 estrogen-mediated decrease in vascular stiffness.  The addition of progesterone 
seems to counteract the estrogen-mediated increase in AC and decrease in PWV, 
indicating that the vascular stiffness-associated cardio-protective effects of HRT, if any, 
may be limited to estrogen administration alone. 
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 5.9 Future Directions 
 
It would be worthwhile to investigate the exact mechanisms underlying the 
estrogen-mediated decrease in vascular stiffness and the counteracting effects of 
progesterone. 
The present study indicates that there are regional differences in the estrogen-
mediated vascular stiffness changes, with greater and more sustained responsiveness of 
aller peripheral vessels (brachial-to-radial) than that of larger central vessels (carotid-
to-femoral).  Future studies shou s for regional differences in 
sponsiveness. 
shown to have vasodilatory properties 
(e.g., renal vasodilation) via the nitric oxide pathway.  Exogenous administration of 
relaxin to nonpregnant female rats (with or without ovaries) and male rats reproduces 
many of the hemodynamic features of pregnancy (increased cardiac output, renal flow, 
and glomerular filtration rate)84,85.  Relaxin can also affect collagen degradation by 
upregulating the expression of matrix metalloproteinase86.  These observations have led 
to the hypothesis that relaxin could favorably alter vascular stiffness, in a manner similar 
sm
ld investigate the reason
re
A search of estrogen alternative is also a worthwhile endeavor.  It has been 
suggested that consumption of isoflavones (naturally occurring estrogen-like compounds) 
is associated with improved chronic disease burden82.  For example, Japanese women 
have lower rates of cardiovascular disease than Western women.  The soy isoflavones can 
stimulate estrogen receptors83 and therefore, could be thought of as an alternative to 
traditional HRT. 
Relaxin, an ovarian hormone, has been 
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 to estrogen.  It is worthwhile to ate to mediate the decline 
 systemic vascular resistance and concomitant rise in global arterial compliance. 
 
 investigate relaxin as a candid
in
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 APPENDIX 
 
 
  
 
 
 
APPENDIX 
 
 
 
Estimating Uncertainty in Calculated Variables Due to Measurement Inaccuracies 
 
 
 Systemic Vascular Resistance (SVR).  Two measured variables are used to SVR: 
mean arterial pressure (MAP) and cardiac output (CO).   
 
CO
MAPSVR = . (A1) 
Thus, the total error in SVR (∆SVR) due to measurement inaccuracies in MAP (∆MAP) 
and CO (∆CO) is given by: 
 CO
CO
SVRMAP
MAP
SVRSVR ∆∂
∂+∆∂
∂=∆   , (A2) 
where  denotes absolute value and  
MAP
SVR
∂
∂
and  
CO
SVR
∂
∂
 represent partial derivatives of 
SVR, given by (from Equation A1): 
 
CO
1 
MAP
SVR =∂
∂
 (A3) 
 2CO
MAP 
CO
SVR −=∂
∂
. (A4) 
Given nominal values of MAP and CO and uncertainties in measured variables 
(∆MAP and ∆CO), one can calculate ∆SVR using Equations A2-A4.  Percentage error can 
now be calculated by dividing ∆SVR by the nominal value of SVR.  
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 Global Arterial Compliance (AC).  The equation for the estimation for AC from 
e diastolic aortic pressure decay method is (same as Equation 3-1): 
 
th
)21 PPSV
AC −(R
Ad=  (A5) 
W  
diastolic pressure), and td (duration of diastole).  P1, aortic pressure at the end of ejection 
2 d
d ure 7, as a function of measured 
e need to write this equation in terms of measured quantities: MAP, CO, Pd (arterial
(Figure 7), is assumed to equal MAP87, P  is the same as P , and SVR = MAP/CO.  In 
order to express A  (area under the diastolic portion, Fig
variables, we have to assign an explicit functional form to the pressure waveform: P(t) 
= ePtP τ= *)( 0 .  We will also assume that this equation exactly passes through MAP (at 
t = 0) and Pd (at t = td) so th
t−
at we can write P0 and τ (and consequently, Ad) in terms of 
measured quantities.  With these considerations, Equation A4 can be rewritten in terms of 
measured quantities as follows:  
 =AC  (A6) 
 d
d
P
MAP
t
MAP
CO
ln
 
Thus, the total error in AC (∆AC) due to measurement inaccuracies can be written as: 
 d
d
d
d
P
P
ACMAP
MAP
ACt
t
ACCO
CO
ACAC ∆∂
∂+∆∂
∂+∆∂
∂+∆∂
∂=∆     , (A7) 
where the partial derivatives are given by: 
 =
d
d


×∂
∂
P
MAPMAP
t
CO
AC
ln
COAC  (A9) 
 (A8) 
 


×
=∂
∂
d
d
P
MAPMAPt ln
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  2 ×=∂
d
PMAPP
ln 


∂ d
dd
P
MAP
tCOAC  (A10) 
 
×
−
×
=∂
∂ d
P
MAPMAPMAP
CO
MAPMAP
t
MAP
CO
MAP
AC
lnln
22
dt . (A11) 
 ddP
Given nominal values of MAP, CO, Pd, and td and uncertainties in measured 
variables (∆MAP, ∆CO, ∆ Pd, and ∆ td), one can calculate ∆AC using Equations A7-A11.  
Percentage error can now be calculated by dividing ∆AC by the nominal value of AC. 
Table 17: Uncertainty in Calculated Variables Due to Measurement Inaccuracies 
 
 Nominal Value Error 
CO (ml/s) 85a 1.0 (ref. 88) 
d
Pd (mmHg) 65a 1.5 (ref. 89) 
 
Measured Variables   
t  (s) 0.6a .0025b 
MAP (mmHg) 90a 1.5d 
  
Calculated Variables   
SVR (dyne.s/cm5) 1411 40 (2.8%) 
AC (mL/mmHg) 1.74 0.27 (15.5%) 
a Present study (Table 2); b Sampling rate in the present study. 
We believe that the calculated percentage error for AC is an overestimation for 
o reasons.  First, in order to represent Ad in terms of measured quantities (
Pd, and td), we had to assume an explicit functional form (exponential) for the diastolic 
pressure decay and force this function to pass through the two end points (MAP and Pd).  
his results in unduly large errors in Ad for given measu
Second, an experimental study90 indicated that AC values derived using noninvasive 
chniques (similar to those in the present study) were 
invasive pressure and flow data (most of the values were within 10% of each other). 
 
tw MAP, CO, 
T rement errors in MAP and Pd.  
te similar to those derived using 
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